Interleukin-6 production in B-cell neoplasias and Castleman's disease: Evidence for an additional paracrine loop

1994 ◽  
Vol 69 (1) ◽  
pp. 25-31 ◽  
Author(s):  
R. Burger ◽  
J. Wendler ◽  
K. Antoni ◽  
G. Helm ◽  
J. R. Kalden ◽  
...  
Keyword(s):  
B Cell ◽  
Interleukin 6 ◽  
Castleman’S Disease ◽  
Castleman's Disease

scholarly journals Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease

Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1360-1367 ◽  
Author(s):  
K Yoshizaki ◽  
T Matsuda ◽  
N Nishimoto ◽  
T Kuritani ◽  
L Taeho ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Nodes ◽  
Acute Phase ◽  
Interleukin 6 ◽  
Acute Phase Proteins ◽  
Castleman’S Disease ◽  
Germinal Centers ◽  
Surgical Removal ◽  
Castleman's Disease ◽  
Lymph Node Hyperplasia

Abstract Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma level of acute phase proteins. It has been reported that clinical abnormalities disappear after the resection of the affected lymph nodes, suggesting that products of lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is a cytokine inducing B-cell differentiation to immunoglobulin-producing cells and regulating biosynthesis of acute phase proteins. This report demonstrates that the germinal centers of hyperplastic lymph nodes of patients with Castleman's disease produce large quantities of IL-6 without any significant production of other cytokines. In a patient with a solitary hyperplastic lymph node, clinical improvement and decrease in serum IL-6 were observed following surgical removal of the involved lymph node. There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities. The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.

ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE

Cytokine ◽  
2002 ◽  
Vol 20 (6) ◽  
pp. 304-311 ◽  
Author(s):  
Asao Katsume ◽  
Hiroyuki Saito ◽  
Yoshiki Yamada ◽  
Keigo Yorozu ◽  
Otoya Ueda ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Interleukin 6 ◽  
Castleman’S Disease ◽  
Castleman's Disease ◽  
Receptor Antibody

Practical Management of Castleman's Disease

2016 ◽  
Vol 136 (1) ◽  
pp. 16-22
Author(s):  
Musa Fares Alzahrani ◽  
Mansoor Radwi ◽  
Heather A. Leitch
Keyword(s):  
Hiv Infection ◽  
Interleukin 6 ◽  
Lymphoproliferative Disorder ◽  
Treatment Options ◽  
Castleman’S Disease ◽  
Human Herpesvirus ◽  
Human Herpesvirus 8 ◽  
Castleman's Disease ◽  
Herpesvirus 8 ◽  
Hiv Negative

Castleman's disease (CD) is a rare lymphoproliferative disorder that is most commonly present in multicentric (MCD) form in association with HIV infection. Interleukin-6 (IL-6) and human herpesvirus-8 (HHV-8) play major roles in MCD pathogenesis. Important treatment options have recently become available, particularly with the introduction of IL-6 and IL-6 receptor inhibitors for the treatment of HIV-negative patients with MCD. Though advances in therapy may improve outcomes in some patients, the prognosis remains guarded, and a stratified approach to the management of MCD is needed.

The analysis of interleukin-6 in patients with systemic IgG4-related plasmacytic syndrome--expansion of SIPS to the territory of Castleman's disease

Rheumatology ◽  
2009 ◽  
Vol 48 (7) ◽  
pp. 860-862 ◽  
Author(s):  
M. Yamamoto ◽  
H. Takahashi ◽  
K. Hasebe ◽  
C. Suzuki ◽  
Y. Naishiro ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Castleman’S Disease ◽  
Castleman's Disease
Sign in / Sign up

Export Citation Format

Share Document